Arthneeti
S

Sigachi Industries Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Sigachi Industries Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹34
Market cap₹995 Cr
P/E30.6
Updated26 Aug 2026
Read4 min read

The short version

FY26 API revenue is expected to reach around INR 70 crores, growing steadily month-on-month from INR 9 crores in Q1. For FY '26, Sigachi expects around INR70 crores revenue from the API segment with an EBITDA margin of 18-20%.

From Sigachi Industries Ltd's Q1 FY26 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

  • FY26 API revenue is expected to reach around INR 70 crores, growing steadily month-on-month from INR 9 crores in Q1.
  • EBITDA margin for API segment projected between 18% to 20%.
  • MCC segment to maintain similar capacity levels (~19,000 MT), with the Hyderabad unit (6,400 MT) being restored post-incident.
  • Partial revenue loss of approx. INR 60 crores from Hyderabad plant in next 6 months, with some recovery from other units (Dahej, Jhagadia).
  • Capacity expansion in CCS facility on track for October 2026 with no significant delays expected.
  • Over 2-3 years, API share in revenue mix expected to increase, possibly reducing MCC’s share from current ~80-85% to around 75%.
  • Working capital days aimed to be reduced from current 193 days to below 90 days by end FY26.
  • Business interruption insurance expected to cover revenue losses and help maintain bottom-line growth despite disruptions.

Profitability & Margins

See what Sigachi Industries Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

- The insurance amount received is expected to cover the entire capex needed to rebuild the Hyderabad facility, including plant, machinery, and building. (Page 14) - Detailed capex estimates are pending full access and assessment of the damaged facility. (Page 14) - The company is planning to resume operations at Hyderabad plant within approximately 6 months. (Page 7) - Commercialization of the new CCS (Co-Processed Cellulose & Starch) facility at Dahej is progressing steadily and expected to be on track by October 2026. (Page 9) - Sigachi has secured terms of reference for an upcoming bulk drug and specialty chemical unit at Orvakal, Andhra Pradesh, reinforcing vertical integration goals. (Page 4) - Collaboration with Respilon Group S.R.O for drug delivery technology indicates a strategic investment in advanced pharma tech. (Page 4) Overall, capex focuses on rebuilding post-incident facilities, expanding CCS capacity, new specialty drug units, and innovation through partnerships.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pha.
Rev 1Mar 2
2OneSource Specialty Pharma Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sigachi Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • No explicit details on the current or expected order book or pending orders were provided in the transcript.
  • The company indicated minimal export orders currently in the API segment, with expected revenue of around INR70 crores by FY '26 driven primarily by domestic and Rest of World (ROW) markets.
  • The management expressed strong customer support despite a recent incident, indicating confidence in regaining and maintaining order volumes post-disruption.
  • Discussions with customers are ongoing to manage business continuity and fulfill supply commitments as capacities normalize.
  • The CCS facility capacity expansion is on track for October 2026, which should support future order fulfillment.
  • Overall, visibility on precise pending order quantities or backlog figures was not shared in the call.

Sigachi Industries Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025

Reported quarterly figures (₹ Cr). Latest: revenue ₹117 Cr, net loss ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Sigachi Industries Ltd's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Sigachi Industries Ltd Q1 FY26 results?

FY26 API revenue is expected to reach around INR 70 crores, growing steadily month-on-month from INR 9 crores in Q1. For FY '26, Sigachi expects around INR70 crores revenue from the API segment with an EBITDA margin of 18-20%.

What is Sigachi Industries Ltd share price analysis?

Sigachi Industries Ltd currently shows a neutral. The stock trades at a P/E of 30.6 with a market cap of ₹995 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sigachi Industries Ltd planning capital expenditure?

The insurance amount received is expected to cover the entire capex needed to rebuild the Hyderabad facility, including plant, machinery, and building.

Keep Sigachi Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.